You may view the responses to previous questions submitted on this site below by clicking on the associated question. The most recent responses appear first.

[Displaying 12 Questions]

Question 1 (Response by Louis Kuritzky, MD): posted 03/15/2008

Given recent reports associating phosphodiesterase type 5 (PDE5) inhibitor therapy with hearing loss, please provide a context for and specific information about this adverse event. Has a causal relationship been established between PDE5 inhibitors and hearing loss?

Question 2 (Response by Jay M. Young, MD):
posted 11/12/07

Prostate cancer (PCa) treatment often causes erectile dysfunction (ED). What can clinicians do to treat ED associated with PCa treatment? How can phosphodiesterase type 5 (PDE5) inhibitors help these patients?

Question 3 (Response by Irwin Goldstein, MD):
posted 10/19/07

Optimal management of erectile dysfunction (ED) requires the partner’s collaboration. When treating ED, which considerations should clinicians take into account regarding the patient’s partner?

Question 4 (Response by Arthur L. Burnett II, MD):
posted 09/24/07

Preventive care is crucial to decreasing the prevalence of coronary heart disease, the leading cause of death in the United States. Studies show that erectile dysfunction (ED) may be a predictor of cardiovascular disease (CVD). How prevalent are cardiovascular risk factors among patients with ED, and what can clinicians do to assess these risk factors and improve preventive medicine for patients with ED?

Question 5 (Response by Robert T. Segraves, MD, PhD):
posted 09/04/07

Erectile Dsyfunction (ED) may develop as a side effect of medication prescribed for depression. How can clinicians treat patients with antidepressant-associated ED?

Question 6 (Response by Robert A. Kloner, MD, PhD):
posted 06/15/07

Contrary to the traditional belief that erectile dysfunction (ED) is a late manifestation of arterial disease, a growing body of evidence indicates that ED may predict cardiovascular disease (CVD). What is the latest evidence that substantiates this paradigm shift, further supporting the link between ED and CVD, and what are the clinical implications?

Question 7 (Response by Tom F. Lue, MD, and David M. Latini, PhD):
posted 03/22/07

The Exploratory and Comprehensive Evaluation of Erectile Dysfunction (ExCEED™) study investigated the relationship between severity of erectile dysfunction (ED) and psychosocial impairment as well as psychological outcomes for men receiving treatment. Why is this study important, and what were the significant results?

Question 8 (Response by Jacob Rajfer, MD): posted 12/04/06

Erectile dysfunction (ED) affects not only the man with the condition but also his partner and their relationship. What is the impact of ED on the partner, and how can she contribute to successful treatment of the patient’s condition? In addition, how can clinicians begin to treat ED as a condition shared by the couple?

Questions posted 11/17/2006

1. Question 1 (Response by Raymond A. Costabile, MD):
   A study by Cameron et al showed that, in many cases, a diagnosis of erectile dysfunction (ED) quickly leads to a diagnosis of other underlying medical conditions. How does the timing of these diagnoses assist clinicians in managing men’s overall health?
   
   
2. Question 2 (Response by Irving Fishman, MD):
   Phosphodiesterase type 5 (PDE5) inhibitors can be purchased and distributed via the Internet and the black market for self-prescribed or recreational use. Have alternate means of access to PDE5 inhibitors and inappropriate use resulted in negative consequences? What information can clinicians relay to their patients to explain why such use is harmful and may have negative effects?

Question 9 (Response by Culley C. Carson III, MD): posted 10/16/2006

Many patients with erectile dysfunction (ED) have comorbid conditions or severe ED that renders them less responsive to on-demand phosphodiesterase type 5 (PDE5) inhibitor therapy. Which patients might benefit from daily or chronic administration of PDE5 inhibitors?

Question 10 (Response by Marian E. Dunn, PhD): posted 09/21/2006

Erectile dysfunction (ED) management involves restoring erectile function while reestablishing the couple’s intimate relationship. Resuming sexual activity after a period of abstinence is difficult for some couples. What psychosocial implications should be considered when managing ED in patients and prescribing a phosphodiesterase type 5 (PDE5) inhibitor?

Question 11 (Response by Vivian A. Fonseca, MD): posted 08/16/2006

Phosphodiesterase type 5 (PDE5) inhibitors are an effective first-line oral therapy for erectile dysfunction (ED). Chronic use of PDE5 inhibitors has improved erectile function further and fostered endothelial rehabilitation. Lifestyle modification has improved erectile function and endothelial function and diminished markers of systemic vascular inflammation. What might persuade clinicians that PDE5 inhibitors plus lifestyle modification can improve erectile function and endothelial function in patients?

Question 12 (Response by Ridwan Shabsigh, MD): posted 07/26/2006

To optimize treatment for erectile dysfunction (ED), clinicians must weigh several patient-specific factors when deciding which phosphodiesterase type 5 (PDE5) inhibitor to recommend. One such factor is planned versus unplanned intimacy. What information should primary care clinicians (PCCs) communicate to their patients regarding this concept, and how does this apply to the PDE5 inhibitors?